Lawrence Morton, MD
Neurology with Special Qualifications in Child Neurology · Richmond, VANPI 1033138698
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (30.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Neurelis, Inc. at 39.3% of the total. Reporting peaked in 2023 at $6,955 and has fallen 92.5% since, to $525 in 2025.
Across 106 payments — averaging $161.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$7K
- Greenwich Biosciences, Inc.$4K
- UCB, Inc.$2K
- Nobelpharma America, LLC$1K
- Eisai Inc.$1K
- SK Life Science, Inc.$580
- plus $1K from 10 others
Across 33 payments — averaging $6727.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GW Research Limited$157K
- Eisai Inc.$48K
- Aquestive Therapeutics, Inc.$16K
What the payments were for
- Consulting fees$5,05430%
- Speaking & faculty fees$5,21930%
- Travel & lodging$2,13512%
- Food & beverage$4,69227%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurelis, Inc. | 16 | $6,732 |
| Greenwich Biosciences, Inc. | 5 | $4,197 |
| UCB, Inc. | 51 | $1,951 |
| Nobelpharma America, LLC | 1 | $1,290 |
| Eisai Inc. | 11 | $1,121 |
| SK Life Science, Inc. | 6 | $580 |
| Livanova USA, Inc. | 4 | $440 |
| Upsher-smith Laboratories LLC | 2 | $165 |
| Novartis | 2 | $136 |
| AstraZeneca | 1 | $134 |
| Biomarin Pharmaceutical Inc. | 1 | $110 |
| Immedica Pharma US, Inc. | 1 | $83 |
| Jazz Pharmaceuticals Inc. | 1 | $77 |
| Acadia Pharmaceuticals Inc | 2 | $45 |
| Neuropace, Inc. | 1 | $38 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VALTOCO$6,459
- Epidiolex$4,179
- HYFTOR$1,290
- Fycompa$841
- Fintepla$366
- VNS Therapy$250
- KOSELUGO$134
- AFINITOR$118
- XCOPRI$115
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$103
How this compares
$17,117 in reported general payments places this provider in the 80th percentile of 23 neurology with special qualifications in child neurology providers in Virginia.
See all neurology with special qualifications in child neurology providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology with special qualifications in child neurology in Richmond
- Mathula ThangarajhRichmond$47K
- Amy HarperRichmond$46K
- Alison AlfordRichmond$13K
- Donald TaylorRichmond$256
- Monica IslamRichmond$236
- Miranda LeeRichmond$85
- Crystal ProudNorfolk$1M
- Michael StruncNorfolk$639K
- Nassim ZecavatiFredericksburg$5K
- Ryan WilliamsNorfolk$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.